ClinConnect ClinConnect Logo
Search / Trial NCT06897566

Barriers to Optimal LDL-C Targets in Patients With Atherosclerotic Cardiovascular Disease

Launched by CAIRO UNIVERSITY · Mar 25, 2025

Trial Information

Current as of April 29, 2025

Not yet recruiting

Keywords

Coronary Artery Disease Ldl C Statins Statin Intolerance Statin Associated Muscle Symptoms

ClinConnect Summary

This clinical trial is studying the challenges that patients with a specific heart condition, called atherosclerotic cardiovascular disease (ASCVD), face in reaching their cholesterol goals, specifically low-density lipoprotein cholesterol (LDL-C) levels. High levels of LDL-C can increase the risk of heart problems, so it's important for these patients to manage their cholesterol effectively. The researchers want to find out how many patients are meeting these targets and what obstacles they encounter in achieving them. This information will help identify ways to improve cholesterol management for patients in the future.

To be eligible for this study, participants need to be between 18 and 80 years old, have a confirmed diagnosis of ASCVD, and have been prescribed high-intensity statin medications (which help lower cholesterol) for at least six months. Those who have recently been diagnosed with ASCVD, cannot take statins due to other health issues, or refuse to participate will not be included. The study is not yet recruiting participants, but once it starts, those involved can expect to answer questions about their experiences and challenges in managing cholesterol. This information could lead to better care and support for patients with similar conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients presenting to cardiology department/ outpatient clinic.
  • Established ASCVD and eligible for high intensity statins for at least six-months.
  • Age between18-to-80y.
  • Exclusion Criteria:
  • Refusal to participate in the survey.
  • Recent diagnosis of ASCVD with indication to high intensity statins for a period \< six-months.
  • Patients with medical limitation or contraindications to statins therapy.
  • Patients with documented diagnosis of homozygous familial hypercholesterolemia.

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported